US drug giant has access to the PhysioLab Modeler software and PhysioLab Simulation Server which, according to Entelos’, “reproduces many of the behaviours and underlying biological attributes of metabolism in diverse patient types.
Pfizer’s use of the technology will focus on assessment of its preclinical portfolio of diabetes and obesity treatment candidates, one of the key therapeutic areas it set out in its R&D refocusing in 2008 .
Julie Thomas Goggin, Entelos’ CEO said:“We are thrilled that our highly predictive, established Metabolism Physiolab platform will be available to Pfizer on a perpetual basis to help accelerate its compound development.